Quick answer
What is known about cagrilintide's half-life in preclinical research? Cagrilintide was designed as a stable, lipidated, long-acting amylin analogue, in contrast to pramlintide, which the design paper says has a short half-life that requires frequent administration (Kruse et al., 2021). The abstracts reviewed for this article describe the design goal but report no numerical half-life, so this article gives none. It explains how half-life is defined and measured in preclinical work, why fatty-acid acylation extends it through albumin binding, how a pharmacokinetic study should be built, and the formula-only arithmetic for preparing a stock from the stated mass and formula. Supplied for laboratory research use only; nothing here is an administration instruction.
Searches for "cagrilintide half-life" expect a number. The honest scientific answer is more structured: half-life depends on species, route, dose, formulation and the analytical method, and the primary design paper for the molecule, as summarized in its abstract, states the aim and the outcome in qualitative terms. This article therefore works at the level of principles and published design rationale. It explains the terms, the molecular strategy and the study design a laboratory would need to measure its own values. It applies the RUO rule strictly: no guidance for any person, concentration math only from the stated mass and formula, and published preclinical parameters only where an abstract reports them. The compound is described on the V8 cagrilintide page, and broader context is in the cagrilintide research overview.
What the product page and the design paper state
The V8 page describes cagrilintide as a long-acting amylin-receptor agonist studied alongside incretin research for receptor-signaling work in assay models. It lists a 10 mg lyophilized presentation, ≥98% HPLC purity, the molecular formula C194H308N54O61, and the sequence "reported on the certificate of analysis, where published". The formula gives an average molar mass of about 4,373 g/mol, which is the working number for any concentration calculation.
The design paper reports the development of "the stable, lipidated long-acting amylin analogue cagrilintide" and some of the structure-activity work that led to its selection. It notes that amylin has a high propensity to form amyloid fibrils, which complicates design, and that the amylin analogue pramlintide, commercially available, has a short half-life that the paper links to a need for three daily administrations. It adds that cagrilintide was in clinical trial for obesity and had been associated with significant body-weight reduction alone and in combination with a GLP-1 analogue (Kruse et al., 2021). Those clinical statements are the paper's own and are quoted for context only; this article does not evaluate them. The key point for a preclinical reader is that prolonged exposure was a design objective, achieved by chemistry, and that the abstract states the objective without giving a half-life figure.
Half-life: what the term means and what it depends on
The elimination half-life of a compound is the time for its concentration in plasma to fall by half during the terminal phase, and for a first-order process it is ln 2 divided by the elimination rate constant, with the rate constant equal to clearance divided by volume of distribution. For protein and peptide drugs the relevant clearance routes include proteolysis, renal filtration and receptor-mediated uptake, and the relative weight of each route differs by molecule and species. Three consequences matter in preclinical work.
- Half-life is not a constant of the molecule. It depends on species, route and sampling window, and a rat value cannot be carried to a mouse or any other species without an explicit scaling argument.
- The route changes the apparent value. After subcutaneous administration, slow absorption can make the terminal slope reflect absorption and not elimination, a "flip-flop" situation, so an intravenous reference arm is needed to separate the two.
- The assay defines what is counted. An immunoassay may count intact peptide plus fragments, whereas LC-MS can distinguish the intact molecule from its metabolites.
How lipidation extends exposure
The strategy behind cagrilintide belongs to a family of designs in which a fatty acid is attached to a peptide so that it binds serum albumin. Early work on insulins acylated with fatty acids showed albumin association constants of the order of 104 to 105 M−1, binding at long-chain fatty-acid sites, and a relationship between binding affinity and the timing of insulin action in vivo (Kurtzhals et al., 1995). The same logic was used for the GLP-1 analogue semaglutide, where the aim was to increase albumin affinity and secure stability against metabolic degradation, and where the fatty acid moiety and linker chemistry were the key features for albumin affinity, receptor potency and prolonged exposure (Lau et al., 2015). Cagrilintide is described as lipidated in its design paper (Kruse et al., 2021). The mechanistic reading is that albumin-bound peptide is protected from clearance and acts as a circulating reservoir, so the effective half-life is longer than that of the unmodified peptide. That reading comes from the design literature of the lipidated class and is not a measurement on cagrilintide in the abstracts reviewed.
| Design feature | Problem it addresses | Source in the literature |
|---|---|---|
| Amino-acid substitutions | Amyloid-forming tendency of native amylin; proteolysis | Kruse et al., 2021 |
| Fatty-acid acylation | Short half-life; albumin binding as a depot | Kurtzhals et al., 1995; Lau et al., 2015 |
| Receptor selection | Amylin receptors are multi-subunit, formed with receptor activity-modifying proteins | Hay et al., 2015 |
Designing a preclinical pharmacokinetic study
A laboratory that needs its own half-life should write the design before the experiment.
- Define species, strain, sex and age, and justify them. Clearance differs with each; see the sibling article on sex and age as design variables.
- Include an intravenous arm if absolute exposure and a true terminal half-life are the goals, and the intended route arm for the question actually being asked.
- Plan the sampling schedule from the expected half-life. Sampling should extend over several half-lives, with dense early points and sparse late points; for a long-acting molecule that can mean days.
- Choose the bioanalytical method first. Decide whether intact peptide, total immunoreactive material, or both will be measured, validate recovery from plasma, and check adsorption to tubes. A study of plasticware effects on peptide measurements illustrates the problem (Goebel-Stengel et al., 2011).
- Account for albumin binding. Total and unbound concentrations differ for a lipidated peptide, and the analytical method should state which is measured.
- Use non-compartmental analysis first. Report area under the curve, clearance, volume of distribution and terminal half-life with the number of points used for the terminal slope.
The in vitro side of characterization, receptor assays, is covered in the overview and the existing library on receptor pharmacology; this article stays on exposure.
Formula-only stock arithmetic
The concentration math needs only the stated mass and the formula. With a molar mass of about 4,373 g/mol (from C194H308N54O61), a vial labeled 10 mg contains 10 mg ÷ 4,373 mg/mmol, or about 2.29 µmol, of peptide on a gross-mass basis. The general relation is: molar concentration = (mass in mg ÷ molar mass in mg/mmol) ÷ volume in mL, in mmol/mL, which equals mol/L. Peptide powder also contains water and counter-ions, so the net peptide content can be below the gross mass and a certificate that reports it should be used to correct the figure. Dilutions follow C1 × V1 = C2 × V2. The reconstitution calculator performs the unit conversions, and peptide reconstitution volume calculations shows the method on generic numbers. No administered amount for any animal is given or implied here; the amount per animal is a decision for each approved protocol and its primary literature.
| Quantity | Formula | Note |
|---|---|---|
| Micromoles per vial | mass (mg) × 1000 ÷ molar mass (g/mol) | Gross-mass basis; correct for net peptide content |
| Stock concentration | micromoles ÷ volume (mL) = mM | Record the diluent and lot |
| Working dilution | C1 × V1 = C2 × V2 | Do from the molar stock, not from mass labels |
| Terminal half-life | ln 2 ÷ terminal rate constant | State the points used for the slope |
Handling, verification and documentation
The product page directs refrigeration at 2–8 °C, −20 °C for long-term, protected from heat, moisture and light. After reconstitution, no validated shelf life is published for this product, so stocks should be divided into single-use portions; the general guidance is in how long reconstituted peptides last and the product-specific cagrilintide purity testing. Identity should be checked by observed mass against about 4,373 Da, which for a molecule of this size appears as a charge-state series in electrospray mass spectrometry. Certificates are explained in how to read a COA, lots can be checked in the COA library, and sourcing is covered in where to buy cagrilintide; the catalog is in the shop.
What this article cannot tell you
It cannot give a half-life, a clearance or a bioavailability for cagrilintide in any species, because the sources reviewed do not report them in their abstracts. A reader who needs those numbers should read the full text and supplementary data of the design paper and any subsequent pharmacokinetic reports. The article also cannot support statements about use in people. Its purpose is to make the next literature search and the next experimental design more precise.
Frequently asked questions
What is cagrilintide's half-life?
The abstracts reviewed give no numerical value. The design paper describes cagrilintide as a stable, lipidated, long-acting amylin analogue, and contrasts it with pramlintide, which has a short half-life.
Why is lipidation used?
Attaching a fatty acid lets a peptide bind serum albumin, which protects it from clearance. This was shown for acylated insulins and used in semaglutide's design.
What is the molar mass used for stock calculations?
About 4,373 g/mol, from the formula C194H308N54O61 on the product page.
How many micromoles are in a 10 mg vial?
About 2.29 µmol on a gross-mass basis, from 10 mg ÷ 4,373 g/mol. Correct for net peptide content if the certificate reports it.
Is half-life the same in every species?
No. It depends on species, route, dose and the analytical method, so values cannot be transferred without a stated scaling argument.
Why include an intravenous arm in a PK study?
To obtain absolute exposure and to separate absorption from elimination, since slow absorption after subcutaneous administration can distort the apparent terminal slope.
Does the article give an amount to administer to animals?
No. It gives only formula-based concentration arithmetic. Amounts come from an approved protocol and the primary literature.
Why measure total and unbound concentrations?
Albumin binding makes them differ for a lipidated peptide, so the assay must state which one it reports.
How should cagrilintide be stored?
Per the product page: refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.
What does the design paper say about amylin analogues?
That amylin forms amyloid fibrils easily, that pramlintide has a short half-life, and that cagrilintide was designed as a stable, lipidated, long-acting analogue.
Research-use statement
All material discussed here is supplied for laboratory research use only; not for human consumption, and not a drug, food or cosmetic.
References
- Kruse T, Hansen JL, Dahl K, Schäffer L, Sensfuss U, Poulsen C, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J. Med. Chem.. 2021;64(15):11183-11194. doi:10.1021/acs.jmedchem.1c00565
- Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochemical Journal. 1995;312(3):725-731. doi:10.1042/bj3120725
- Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J. Med. Chem.. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacological Reviews. 2015;67(3):564-600. doi:10.1124/pr.115.010629
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR. The importance of using the optimal plasticware and glassware in studies involving peptides. Analytical Biochemistry. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
